Your browser doesn't support javascript.
loading
Safety and efficacy of unilateral topical application of rocuronium bromide in healthy scops owls (Otus scops).
Cantero, Francisco; Ortillés, Ángel; Peña, María T; Gogova, Savina; Molina, Rafael; Ríos, José; Leiva, Marta.
Affiliation
  • Cantero F; Servei d'Oftalmologia, Fundació Hospital Clínic Veterinari, Universitat Autònoma de Barcelona, Bellaterra, Spain.
  • Ortillés Á; Departament de Medicina i Cirurgia Animals, Facultat de Veterinària, Universitat Autònoma de Barcelona, Bellaterra, Spain.
  • Peña MT; Servei d'Oftalmologia, Fundació Hospital Clínic Veterinari, Universitat Autònoma de Barcelona, Bellaterra, Spain.
  • Gogova S; Departament de Medicina i Cirurgia Animals, Facultat de Veterinària, Universitat Autònoma de Barcelona, Bellaterra, Spain.
  • Molina R; Servei d'Oftalmologia, Fundació Hospital Clínic Veterinari, Universitat Autònoma de Barcelona, Bellaterra, Spain.
  • Ríos J; Departament de Medicina i Cirurgia Animals, Facultat de Veterinària, Universitat Autònoma de Barcelona, Bellaterra, Spain.
  • Leiva M; Servei d'Oftalmologia, Fundació Hospital Clínic Veterinari, Universitat Autònoma de Barcelona, Bellaterra, Spain.
Vet Ophthalmol ; 24(2): 169-176, 2021 Mar.
Article de En | MEDLINE | ID: mdl-33400365
ABSTRACT

OBJECTIVE:

To evaluate the safety and efficacy of unilateral topical application of rocuronium bromide in scops owls. ANIMALS STUDIED Ten healthy adult scops owls. PROCEDURES Birds weighting between 82-111 g were enrolled. Complete physical and ophthalmic examinations were performed. Each animal received a single dose of 0.15 mg of rocuronium bromide (30 µL) in a randomly selected eye. Static pupillometric evaluations were performed before and after drug instillation at 0, 30, 60, 90, and 120 minutes, in a room with fixed light intensity. Physical and ophthalmic examinations were carried out to evaluate possible adverse effects.

RESULTS:

Median pupil (95% CI) size at t0 was 7.10 mm (5.51-7.41) for placebo eyes and 7.22 mm (6.93-7.48) for treated eyes, showing no statistical differences (P > .05). When compared to the placebo eye, significant mydriasis was achieved at t30 [8.18 mm (7.22-9.00)] (P = .014) and lasting until t90 [7.35 mm (6.20-9.52)] (P = .004). Maximal mydriasis was obtained at t60 [8.63 mm (7.72-9.81)] (P = .001). During this period, the treated eye no longer responded to direct light stimulation. Complete mydriasis was observed in 5/10 birds (mean weight 97.4 g). Pupil size at t90 and t120 did not differ from baseline (P > .05) in treated eyes. No adverse effects were seen during the study period.

CONCLUSION:

Single-dose topical rocuronium bromide (0.15 mg) is a safe and effective medium duration mydriatic agent in scops owls. Further studies are needed to evaluate bilateral topical application and standardize the mydriatic protocol.
Sujet(s)
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Strigiformes / Rocuronium / Mydriatiques Limites: Animals Langue: En Journal: Vet Ophthalmol Sujet du journal: MEDICINA VETERINARIA / OFTALMOLOGIA Année: 2021 Type de document: Article Pays d'affiliation: Espagne

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Strigiformes / Rocuronium / Mydriatiques Limites: Animals Langue: En Journal: Vet Ophthalmol Sujet du journal: MEDICINA VETERINARIA / OFTALMOLOGIA Année: 2021 Type de document: Article Pays d'affiliation: Espagne